

RECEIVED 642

NOV 3 0 2000

## WILLIAMS, MORGAN & AMERSON, P.C.

7676 HILLMONT, SUITE 250, HOUSTON, TX 77040 (713) 934-7000 Fax (713) 934-7011

TECH CENTER 1868/2900

Danny L. Williams
Terry D. Morgan
J. Mike Amerson
Kenneth D. Goodman
Barbara S. Kitchell, Ph.D.
Jeffrey A. Pyle
Randall C. Furlong, Ph.D.

Scott F. Diring\*
George J. Oehling\*
Shelley P.M. Fussey, Ph.D.\*
Mark D. Moore, Ph.D.\*
Louis H. Iselin, Ph.D.\*
Raymund F. Eich, Ph.D.\*
Bradley A. Misley\*

Thomas H. Belvin, Jr.\*

\*Patent Agent

WRITER'S DIRECT DIAL: (713) 934-4079

November 20, 2000

FILE: 4001.002282

## CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date below:

November 20, 2000

Date

Shelley P.M. Fussey

Assistant Commissioner for Patents Washington, DC 20231

RE: U.S. Patent Application Serial No. 09/351,862; Entitled: "Cancer Treatment Kits Using Antibodies to Aminophospholipids"; Inventors: Thorpe and Ran; Client Reference: UTSMC/DAL:549--1

Sir:

į

Enclosed for filing in the above-referenced patent application is:

- (1) A Supplemental Information Disclosure Statement, PTO Form 1449 and copies of References A19 and A20; and
- (2) A postcard listing these materials; please date stamp and return the postcard evidencing receipt of these materials.

WILLIAMS, MORGAN & AMERSON, P.C.
Assistant Commissioner for Patents
November 20, 2000
Page 2

No additional fees are believed to be due in connection with the filing of these materials. However, should additional fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason, the Assistant Commissioner is hereby authorized to deduct said fees from Williams, Morgan & Amerson, P.C. Deposit Account No. 50-0786/4001.002282.

Respectfully submitted,

Shelley P.M. Fussey, Ph.D.

Reg. No. 39,458 Patent Agent

Encls.



## CERTIFICATE OF MAILING 37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner.for Patents, Washington, D.C. 20231, on the date below:

November 20, 2000

Date

RECEIVED

NOV 3 0 2000

TECH CENTER 1600/2900

**PATENT** 

#12/2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Philip E. Thorpe and Sophia Ran

Serial No.: 09/351,862

Filed: July 12, 1999

For: CANCER TREATMENT KITS USING

ANTIBODIES TO

**AMINOPHOSPHOLIPIDS** 

Group Art Unit: 1642

Strellev P.M. Fussev

Examiner: Helms, L.

Atty. Dkt. No.: 4001.002282

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents -Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record in the present case. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the

receipt of a first Official Action reflecting an examination on the merits, and hence is timely filed

in accordance with 37 C.F.R § 1.97(b). Therefore, no fees should be due in connection herewith.

Even if an Official Action had issued in the last few days, no fee would still be due to formally

enter the listed documents into the record in light of the following certification.

In accordance with 37 C.F.R. § 1.97(e)(2), Applicants undersigned representative hereby

certifies that no item of information contained in this Supplemental Information Disclosure

Statement was cited in a communication from a foreign patent office in a counterpart foreign

application. The listed documents were cited in the first Official Action on the merits in

co-pending application Serial No. 09/351,149 (Attorney Docket No. 3999.002383) mailed from

the PTO on November 07, 2000, less than three months before the filing of the present statement,

and evidently could not have been submitted before receipt. The present Supplemental

Information Disclosure Statement would thus be timely filed in accordance with 37 C.F.R.

§ 1.97(c).

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason

relating to these materials, the Examiner should contact the undersigned representative to discuss

deduction from Williams, Morgan & Amerson Deposit Account No. 50-0786/4001.002282.

Respectfully submitted,

Shelley P.M. Fussey Reg. No. 39,458

Agent for Applicant

WILLIAMS, MORGAN & AMERSON, P.C.

7676 Hillmont, Suite 250

Houston, Texas, 77040

(713) 934-4079

Date: November 20, 2000

2